Low-Dose Testosterone and Diphenhydramine Interaction: What Women Need to Know

Why This Interaction Matters for Women Specifically

Low-dose testosterone is prescribed off-label to women, most often for hypoactive sexual desire disorder (HSDD), and its use is rising in perimenopausal and postmenopausal women. Diphenhydramine, an over-the-counter first-generation antihistamine, is one of the most commonly self-administered drugs in the United States, routinely used for sleep, allergic rhinitis, and itch. Because diphenhydramine is sold without a prescription, women frequently do not mention it to the clinician managing their testosterone therapy.

The combination is not a hard contraindication. However, the pharmacodynamic overlap between these two agents creates compounding risks that are especially relevant to women whose hormonal environment is already shifting. Understanding what each drug does to the brain, and how the female hormonal milieu modifies that effect, allows for genuinely informed decisions rather than reflexive avoidance or reflexive dismissal.

Who Is Taking Low-Dose Testosterone and Why

In women, testosterone is used at doses roughly one-tenth those prescribed for men, typically in the range of 0.5 to 2 mg/day via compounded transdermal cream or gel. The Global Consensus Position Statement on testosterone therapy for women published in 2019 supports its use for postmenopausal HSDD at doses that achieve physiologic premenopausal serum levels, targeting total testosterone of approximately 15-60 ng/dL. No testosterone formulation is currently FDA-approved for women in the United States, meaning all female testosterone therapy is off-label or compounded.

The women most likely to be on this therapy are postmenopausal (natural or surgical), perimenopausal, or occasionally those with premature ovarian insufficiency. Younger women in their reproductive years are prescribed testosterone far less often, though some receive it for HSDD or androgen insufficiency related to hypopituitarism.

Who Is Taking Diphenhydramine and Why

Sleep disturbance is reported by 40-60% of perimenopausal and postmenopausal women, making this life stage the demographic most likely to reach for an OTC sleep aid. Diphenhydramine is the active ingredient in Benadryl, ZzzQuil, Unisom SleepTabs, and many combination cold-allergy products. At a standard dose of 25-50 mg, it produces sedation through H1-receptor antagonism in the CNS and blocks muscarinic acetylcholine receptors, generating its characteristic anticholinergic side effects: dry mouth, blurred vision, urinary retention, constipation, and cognitive slowing.

The Pharmacology of Each Drug in Women

Testosterone Pharmacokinetics in Women

Transdermal testosterone in women bypasses first-pass hepatic metabolism. After absorption through skin, testosterone circulates bound predominantly to sex hormone-binding globulin (SHBG) and albumin; only about 1-3% is free and biologically active. SHBG levels are directly relevant because oral estrogen raises SHBG by 100-200%, meaning women on oral estrogen-containing HRT who add testosterone may need higher testosterone doses to achieve equivalent free testosterone levels compared with women on transdermal estrogen or no estrogen at all.

Testosterone is metabolized primarily by CYP3A4 in the liver. It is also a substrate for aromatase (CYP19A1), which converts a fraction to estradiol, and 5-alpha-reductase, which converts it to dihydrotestosterone (DHT). At female physiologic doses, these conversion pathways operate at low throughput and rarely produce clinically meaningful hormonal excess unless compounded products are dosed imprecisely.

Diphenhydramine Pharmacokinetics

Diphenhydramine is rapidly absorbed orally with peak plasma concentration at 2-3 hours. It is metabolized primarily by CYP2D6, with lesser contributions from CYP1A2 and CYP2C9. It is not a significant CYP3A4 substrate, which is the primary testosterone metabolizing enzyme. This means the two drugs do not share a metabolic enzyme pathway in a clinically relevant way, and a classical pharmacokinetic interaction (one drug raising the blood level of the other) is not expected.

What Does Interact: Pharmacodynamic Overlap

The interaction between testosterone and diphenhydramine is pharmacodynamic, not pharmacokinetic. Both agents act on the central nervous system through distinct but overlapping mechanisms.

Testosterone has well-documented effects on CNS function in women. Androgen receptors are expressed throughout the brain, including the hippocampus, prefrontal cortex, and limbic structures. At physiologic levels, testosterone in women is associated with improved mood, motivation, and sleep quality. However, supraphysiologic testosterone concentrations are linked to irritability, acne, clitoral enlargement, and in some women, mood dysregulation.

Diphenhydramine crosses the blood-brain barrier readily. Its CNS effects include sedation, impaired working memory, and reduced cognitive processing speed. The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults, published by the American Geriatrics Society, explicitly lists diphenhydramine and all first-generation antihistamines as medications to avoid in adults over 65 because of the risk of confusion, cognitive impairment, and falls.

The practical consequence: if a woman on testosterone therapy is already experiencing any degree of hormone-related CNS effect (sleep changes, mood shifts, or fatigue, which are common during testosterone initiation), adding diphenhydramine amplifies CNS burden and makes it harder to distinguish medication side effects from hormonal adjustment.

Anticholinergic Burden and the Menopausal Brain

A framework clinicians rarely communicate to patients is anticholinergic burden scoring. The Anticholinergic Cognitive Burden (ACB) scale assigns each anticholinergic drug a score from 1 to 3 based on its affinity for muscarinic receptors and evidence of cognitive harm. Diphenhydramine scores a 3, the highest possible rating, indicating definite cognitive anticholinergic effects. Testosterone itself has no direct anticholinergic activity and scores 0.

Why this matters for the menopausal brain: estrogen and testosterone both modulate cholinergic neurotransmission. The loss of estrogen at menopause reduces acetylcholine synthesis and receptor sensitivity in areas critical to memory and attention. A woman on testosterone therapy during perimenopause or postmenopause is, in effect, attempting partial neuroprotection of a system already under hormonal stress. Layering diphenhydramine on top directly antagonizes acetylcholine at those same brain circuits. The additive cognitive burden from a single-night 50 mg diphenhydramine dose may be clinically trivial in a 35-year-old, but meaningfully impactful in a 55-year-old whose cholinergic tone is already diminished.

A 2019 JAMA Internal Medicine prospective cohort study found that cumulative exposure to anticholinergic medications with ACB scores of 3 was independently associated with increased dementia risk, with a dose-response relationship. The testosterone interaction does not create additional dementia risk by itself. The relevant message for women: chronic diphenhydramine use is problematic in its own right during and after menopause, and the concurrent hormonal context makes it worth taking seriously.

Severity Classification and Clinical Monitoring

Formal Interaction Database Classification

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not list testosterone-diphenhydramine as a named specific interaction. This absence reflects the limited representation of women in pharmacologic interaction studies, not the absence of pharmacodynamic concern. The interaction is best classified as moderate severity based on the additive CNS depression mechanism, consistent with how those same databases classify diphenhydramine combined with other CNS-active agents.

What to Monitor

If a woman is using diphenhydramine occasionally while on low-dose testosterone, the following clinical parameters are worth tracking:

• Next-day sedation or cognitive fog beyond what she expects from diphenhydramine alone
• Mood changes: irritability or low mood that appears shortly after combined use
• Sleep architecture: diphenhydramine suppresses REM sleep, and testosterone is associated with improved sleep depth; these mechanisms may partially conflict
• Urinary symptoms: diphenhydramine's anticholinergic effects can worsen bladder symptoms in postmenopausal women who already have genitourinary syndrome of menopause (GSM)-related urinary urgency or frequency

Dose Adjustment

No dose adjustment to the testosterone regimen is required based on diphenhydramine use. The testosterone dose should be guided by symptom response and serum total testosterone levels, targeting the physiologic premenopausal range as outlined in the Global Consensus Position Statement. Diphenhydramine should be kept to the lowest effective dose (25 mg rather than 50 mg) and used for the shortest duration necessary.

Life Stage Differences: Who Faces the Most Risk

Postmenopausal Women

This group carries the highest risk from this combination. Sleep disruption, cognitive change, and urinary symptoms are already common in the postmenopausal period. Adding a high-ACB antihistamine to a CNS-active androgen therapy compounds existing vulnerabilities. For postmenopausal women with both HSDD (addressed by testosterone) and insomnia (the reason they reach for diphenhydramine), the better path is to treat the insomnia separately with an evidence-based agent such as cognitive behavioral therapy for insomnia (CBT-I), which is the first-line recommendation from the American Academy of Sleep Medicine, or low-dose doxepin 3-6 mg, which has a very different receptor profile and does not carry the same anticholinergic burden as diphenhydramine.

Perimenopausal Women

Perimenopausal women experience the most hormonal variability. Testosterone levels fluctuate alongside estradiol, and progesterone loss in the late perimenopause stage is a primary driver of sleep disruption. In this group, the testosterone dose should be established and stable before introducing any OTC sleep aid. Diphenhydramine tolerance develops rapidly, often within 3-4 nights of consecutive use, meaning it becomes ineffective as a sleep aid while anticholinergic burden persists.

Reproductive-Age Women

Women in their reproductive years who take low-dose testosterone (for hypopituitarism-related androgen deficiency or off-label for HSDD) are less likely to have the same cholinergic vulnerability as older women. Occasional diphenhydramine for acute allergy or short-duration sleep need carries lower net risk in this age group. The primary concerns shift to contraception and pregnancy avoidance (see below).

Postpartum and Lactating Women

Testosterone therapy is not indicated in the postpartum period for HSDD; postpartum libido changes are driven primarily by prolactin elevation, sleep deprivation, and estrogen suppression from lactation rather than androgen deficiency. This life stage is not a typical clinical scenario for testosterone prescribing.

Pregnancy, Lactation, and Contraception: Required Reading

Testosterone is FDA Pregnancy Category X. This classification means that fetal risk has been demonstrated and the risks clearly outweigh any potential benefit. Testosterone causes virilization of female fetuses, including ambiguous genitalia and other masculinizing effects on the external and internal genitalia. There is no safe dose in pregnancy.

Any woman of reproductive potential who is prescribed testosterone must use reliable contraception throughout treatment. This is not a theoretical risk. Compounded testosterone cream applied to the skin can transfer to partners and, if a woman is not protected, to a fetus. Patients should be counseled explicitly on this point at initiation.

Regarding lactation: testosterone transfers into breast milk. Formal lactation pharmacokinetic data in women using low-dose compounded testosterone are sparse, and the LactMed database maintained by the National Institutes of Health advises caution. The general clinical recommendation is to avoid testosterone therapy during lactation, with the exception of extraordinary clinical circumstances managed by a specialist.

Diphenhydramine in pregnancy carries FDA Pregnancy Category B for most indications, though its use in the first trimester warrants caution given limited human teratogenicity data. It passes into breast milk and may cause sedation in nursing infants. The AAP has historically classified it as compatible with breastfeeding with monitoring, but many lactation specialists recommend shorter-acting antihistamines such as loratadine or cetirizine as preferred alternatives.

The combined scenario of a pregnant or lactating woman taking both testosterone and diphenhydramine is clinically implausible in appropriate prescribing, because testosterone is absolutely contraindicated in pregnancy and not recommended during lactation. If a woman discovers she is pregnant while on testosterone therapy, she should stop testosterone immediately and contact her prescriber.

Female-Relevant Conditions This Interaction Touches

Low-dose testosterone therapy in women sits at the intersection of several conditions relevant to women's health:

HSDD: The primary indication for testosterone in women. HSDD affects approximately 10% of premenopausal and up to 30-40% of postmenopausal women. Sleep quality and mood are tightly linked to sexual desire, meaning any agent that disrupts either (including diphenhydramine) indirectly works against the therapeutic goal.

PCOS: Women with polycystic ovary syndrome often already have elevated endogenous testosterone. Adding exogenous testosterone in this population is generally not appropriate for HSDD, and combining it with diphenhydramine adds no specific additional interaction risk beyond the general CNS concerns described above.

GSM (Genitourinary Syndrome of Menopause): Diphenhydramine's anticholinergic effects worsen lower urinary tract symptoms, including urgency, frequency, and dysuria. Women with GSM who are also on testosterone for HSDD should be counseled that diphenhydramine can worsen bladder symptoms specifically.

Osteoporosis: No direct interaction with this combination for bone health. Testosterone has weak anabolic effects on bone in women, but this is not the primary reason it is prescribed and should not influence decisions about diphenhydramine use.

Female Pattern Hair Loss: High doses of testosterone (from dosing errors in compounded preparations) can accelerate androgenic alopecia in women. This is unrelated to diphenhydramine.

Evidence Gaps: What We Do Not Know

Women have been historically underrepresented in pharmacokinetic and drug interaction research. The testosterone-diphenhydramine combination has no dedicated interaction study in women. The evidence base draws from:

1. Female-specific testosterone pharmacokinetic studies (primarily from the Intrinsa patch trials and the APHRODITE study)
2. Anticholinergic burden literature in aging women
3. CYP enzyme interaction databases that confirm no pharmacokinetic overlap

What remains unstudied: whether the hormonal environment created by concurrent testosterone therapy meaningfully changes diphenhydramine CNS effects at the receptor level in women, and whether there are individual pharmacogenomic factors (CYP2D6 poor metabolizers, for example) who experience disproportionate diphenhydramine exposure with this combination.

CYP2D6 poor metabolizers achieve 2-fold higher diphenhydramine plasma concentrations than extensive metabolizers. A woman who is a CYP2D6 poor metabolizer on testosterone may experience substantially greater sedation and anticholinergic effect from a standard 25 mg dose than her total genetic status predicts. This is a known gap in personalized medicine for women and represents an area where pharmacogenomic testing could eventually guide safer OTC antihistamine selection.

Safer Alternatives for Sleep and Allergy in Women on Testosterone

When a woman on testosterone therapy needs treatment for sleep or allergy, the following alternatives carry less CNS and anticholinergic burden:

For allergic rhinitis or acute allergic reactions:

• Loratadine (Claritin) 10 mg daily: non-sedating, does not cross the blood-brain barrier in significant amounts, no meaningful anticholinergic activity
• Cetirizine (Zyrtec) 10 mg daily: mildly sedating in some women but far lower ACB score than diphenhydramine
• Fexofenadine (Allegra) 180 mg daily: non-sedating, minimal CNS penetration

For sleep:

• CBT-I: the first-line treatment for chronic insomnia and effective in menopausal women specifically
• Melatonin 0.5-3 mg: no anticholinergic burden, no interaction with testosterone metabolism
• Low-dose doxepin 3-6 mg: FDA-approved for sleep-onset insomnia, different receptor profile, lower anticholinergic burden than diphenhydramine at these doses, though still warrants discussion with your prescriber
• Addressing the root hormonal cause: in many postmenopausal women, insomnia driven by vasomotor symptoms responds to HRT optimization, and the need for a sleep aid may decrease after testosterone and estrogen are properly dosed

Patient Counseling Summary

If you are taking low-dose testosterone and considering diphenhydramine, tell your prescribing clinician. The combination is not prohibited, but it is not trivial, especially during and after menopause. If you use diphenhydramine, limit it to the lowest dose (25 mg) for the fewest nights necessary, and avoid it on nights when you need to be mentally sharp the next day. Do not use it as a long-term sleep strategy; tolerance develops within days and the anticholinergic effect persists.

A second-generation antihistamine (loratadine, cetirizine, fexofenadine) is a straightforward substitute for allergy symptoms and eliminates the anticholinergic concern entirely. For sleep, raising the issue with your testosterone prescriber often reveals an underaddressed hormonal cause, particularly vasomotor symptoms or inadequate progesterone support, that is better treated directly than masked with an OTC sedative.